phrykt

Relmada Therapeutics, Inc. (RLMD): who owns it and who trades it

As of Nov 16, 2026, RLMD insiders reported 6 purchases worth $1.8M in the last 12 months. The largest buyer was Sergio Traversa (CEO), with $941K. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Relmada Therapeutics

From the latest filings

Overall: more buying than selling. Funds, insiders and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RLMD

126 funds and institutions reported RLMD shares worth $696M at the end of Q2 2026, about 96% of the company. The largest holder is Jupiter Topco LLC with 10.6%.

Funds and institutions (13F) 96%Everyone else 4%

10 largest owners, by share of the company

Jupiter Topco LLC10.6%
BlackRock, Inc.7.1%
Squadron Capital Management LLC7.0%
Venrock Adviser, LLC6.5%
Spruce Street Capital LP6.1%
Adage Capital Partners Gp, L.l.c.4.5%
Vanguard Capital Management LLC4.3%
Jones Hill Capital LP3.5%
Orbimed Advisors LLC3.5%
State Street Corp2.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Jupiter Topco LLC11.16M10.64%$77.3M–
BlackRock, Inc.7.43M7.08%$51.4M+476%
Squadron Capital Management LLC7.35M7.01%$50.9M-13%
Venrock Adviser, LLC6.84M6.53%$47.4M+41%
Spruce Street Capital LP6.39M6.09%$44.2M+2%
Adage Capital Partners Gp, L.l.c.4.76M4.54%$33MNo change
Vanguard Capital Management LLC4.46M4.25%$30.9M+45%
Jones Hill Capital LP3.66M3.48%$25.3M+966%
Orbimed Advisors LLC3.63M3.46%$25.1M-23%
State Street Corp2.52M2.40%$17.4M+605%
Geode Capital Management, LLC2.49M2.38%$17.3M+194%
Millennium Management LLC2.36M2.25%$16.3M-40%
Marshall Wace, LLP2.25M2.14%$15.5M-50%
Ikarian Capital, LLC2.15M2.05%$14.9M-20%
Driehaus Capital Management LLC2.13M2.03%$14.8MNo change
Ameriprise Financial Inc1.94M1.85%$13.4M+263%
Eventide Asset Management, LLC1.86M1.77%$12.9M+121%
Balyasny Asset Management L.P.1.52M1.45%$10.5M+502%
Stempoint Capital LP1.46M1.39%$10.1M+22%
Commodore Capital LP1.43M1.36%$9.9M+125%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RLMD insiders reported $1.8M of open-market purchases and $0 of sales.

Purchases, 12 months
$1.8M
6 trades, 2 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Sep 10, 2026
Filed Sep 11, 2026

Purchases and sales by month

$1.7M$1.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 10, 2026Maged ShenoudaCFOPurchase79,800$4.25$339KForm 4
Sep 10, 2026Sergio TraversaCEOPurchase100,000$4.10$410KForm 4
Sep 9, 2026Maged ShenoudaCFOPurchase120,200$4.20$505KForm 4
Sep 9, 2026Sergio TraversaCEOPurchase100,000$4.18$418KForm 4
Dec 15, 2025Sergio TraversaCEOPurchase27,500$4.12$113KForm 4
Dec 15, 2025Maged ShenoudaCFOPurchase11,665$4.12$48.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Sergio TraversaChief Executive Officer, Director$941K–Sep 10, 2026
Maged ShenoudaChief Financial Officer$892K–Sep 10, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RLMD short interest

High short interest. 10.2% of RLMD shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 98%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.84M RLMD shares were sold short, 10.2% of the shares outstanding, down 11.0% from the report before. At the average daily volume of 1.70M shares, buying them all back would take about 6.4 trading days (days to cover).

Shares short, % of all shares

10.2%May 15Oct 3014.8%

Days to cover

6.4May 15Oct 3019.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.84M10.16%-11%1.70M6.4
Oct 15, 202612.18M11.42%-9%1.43M8.5
Sep 30, 202613.42M12.58%-7%1.03M13.0
Sep 15, 202614.46M13.56%+6%1.56M9.2
Aug 31, 202613.60M12.75%+5%768,19117.7
Aug 14, 202612.89M12.09%-5%1.38M9.3
Jul 31, 202613.56M12.93%+4%1.74M7.8
Jul 15, 202612.99M12.38%+22%1.54M8.5
Jun 30, 202610.65M10.15%+76%3.47M3.1
Jun 15, 20266.06M5.78%+4%1.37M4.4
May 29, 20265.84M5.57%+6%961,5236.1
May 15, 20265.49M5.23%+3%898,2316.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Relmada Therapeutics company events

Relmada Therapeutics filed 8 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Sep 8, 2026.

  1. Sep 8, 2026AnnouncementDr. Raj S. Pruthi’s employment as Chief Medical Officer – Urology of Relmada Therapeutics, Inc., ended on September 3, 2026. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned… Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jul 28, 2026AnnouncementShared information with investors. Filing
  4. May 28, 2026VoteReported shareholder vote results. Filing
  5. May 12, 2026ResultsReleased financial results. Filing
  6. Mar 20, 2026ResultsReleased financial results. Filing
  7. Mar 9, 2026AgreementRelmada Therapeutics, Inc. entered into a Securities Purchase Agreement for a private placement with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). Filing
  8. Dec 15, 2025LeadershipThe Board of Directors the Board of Directors of Relmada Therapeutics, Inc. approved an amended and restated employment agreement with each of its executive officers, each to become effective as of January 1, 2026. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Relmada Therapeutics financials

Famous investors that hold RLMD

3 of the 50 well-known investors we track reported holding RLMD in their latest 13F filing. The largest position is Israel Englander's, worth $12.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20263.35M$12.6M0.0%+42%
Jim Simons · Renaissance TechnologiesQ3 2026503,192$1.9M0.0%+771%
Ken Griffin · Citadel AdvisorsQ3 2026442,103$1.7M0.0%-58%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named RLMD in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Squadron Master Fund LP13G/A3.3%
Nov 16, 2026Squadron Master Fund LP13G/A3.3%

Questions about Relmada Therapeutics, Inc. (RLMD) stock

Who owns the most RLMD stock?

The largest reported owner of Relmada Therapeutics, Inc. (RLMD) is Jupiter Topco LLC, with 10.6% of the company. In total, 126 funds and institutions reported holding RLMD at the end of Q2 2026, together about 96% of the shares. See the largest owners.

Are RLMD insiders buying or selling?

In the last 12 months, RLMD insiders reported 6 open-market purchases worth $1.8M and no sales. The latest trade was on Sep 10, 2026. See every trade.

What is the short interest in RLMD?

As of Oct 30, 2026, 10.84M RLMD shares were sold short, 10.2% of the shares outstanding, down 11.0% from the report before. At the average daily volume of 1.70M shares, buying them all back would take about 6.4 trading days (days to cover). See the history.

Which famous investors hold RLMD?

3 of the 50 well-known investors we track reported RLMD in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $12.6M. See all holders.

Executive pay

Relmada Therapeutics's chief executive was paid a total of $8.9M for the year ended Dec 31, 2025, up 394% from $1.8M the year before. In the last 12 months, Relmada Therapeutics's executives and directors bought $1.8M of stock on the open market and sold none.

Chief executive, total pay$8.9MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$19.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$5.6MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.